Esperion Therapeutics Inc
NASDAQ:ESPR

  • LAST PRICE
    2.1100
  • TODAY'S CHANGE (%)
    -0.0100 (-0.4717%)
  • Bid / Lots
    2.1200/ 1
  • Ask / Lots
    2.1300/ 2
  • Open / Previous Close
    2.1300 / 2.1200
  • Day Range
    2.0300
    2.1800
  • 52 Week Range
    0.7060
    3.4000
  • Volume
    2,893,325

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ESPR
Esperion Therapeutics Inc
416.0M
-2.4x
---
RIGL
Rigel Pharmaceuticals Inc
275.0M
-18.6x
---
SIGA
SIGA Technologies Inc
485.3M
6.1x
-28.78%
BVNRY
Bavarian Nordic A/S
2.5B
24.2x
---
DSNKY
Daiichi Sankyo Co Ltd
64.3B
41.1x
---
LFCR
Lifecore Biomedical Inc
169.8M
137.0x
+27.97%
As of 2024-10-18

Company Information

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Contact Information

Headquarters
3891 Ranchero Drive Suite 150, Suite 300ANN ARBOR, MI, United States 32960
Phone
734-887-3903
Fax
302-655-5049

Executives

Independent Chairman of the Board
J. Martin Carroll
President, Chief Executive Officer, Director
Sheldon Koenig
Chief Financial Officer
Benjamin Halladay
General Counsel
Benjamin Looker
Chief Commercial Officer
Eric Warren

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$416.0M
Revenue (TTM)
$277.8M
Shares Outstanding
196.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.99
EPS
$-0.88
Book Value
$-3.85
P/E Ratio
-2.4x
Price/Sales (TTM)
1.5
Price/Cash Flow (TTM)
---
Operating Margin
-17.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.